MCID: PRP036
MIFTS: 57

Peripheral T-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Peripheral T-Cell Lymphoma

MalaCards integrated aliases for Peripheral T-Cell Lymphoma:

Name: Peripheral T-Cell Lymphoma 38 12 76 53 15 73
Peripheral T Cell Lymphoma 37
Lymphoma T-Cell Peripheral 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050749
KEGG 37 H01892
ICD10 33 C84.4
UMLS 73 C0079774

Summaries for Peripheral T-Cell Lymphoma

Disease Ontology : 12 A mature T-cell and NK-cell lymphoma includes a group of T-cell lymphomas that develop away from the thymus.

MalaCards based summary : Peripheral T-Cell Lymphoma, also known as peripheral t cell lymphoma, is related to lymphoma and angioimmunoblastic t-cell lymphoma, and has symptoms including pruritus An important gene associated with Peripheral T-Cell Lymphoma is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Beleodaq and Folotyn have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and thymus, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Peripheral T-cell lymphoma refers to a group of T-cell lymphomas that develop away from the... more...

Related Diseases for Peripheral T-Cell Lymphoma

Diseases related to Peripheral T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 188)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.0 ALK BCL6 TCL1A TNFRSF8
2 angioimmunoblastic t-cell lymphoma 32.0 BCL6 CXCL13 GZMB ITK MME SYK
3 anaplastic large cell lymphoma 31.0 ALK GZMB TNFRSF8
4 diffuse large b-cell lymphoma 30.6 BCL6 CD5 MME TNFRSF8
5 cutaneous t cell lymphoma 30.5 CCR4 GZMB IL2 TIA1 TNFRSF8
6 alk-negative anaplastic large cell lymphoma 30.5 ALK CCR4 CXCR3
7 lethal midline granuloma 30.5 NCAM1 TIA1
8 composite lymphoma 30.4 BCL6 CD5 GZMB TIA1
9 lymphoma, hodgkin, classic 30.4 ALK BCL6 CD5 MME
10 mycosis fungoides 30.4 CCR4 CXCR3 GZMB IL2 TIA1 TNFRSF8
11 panniculitis 30.3 GZMB NCAM1 TIA1
12 marginal zone b-cell lymphoma 30.2 BCL6 CD5 MME
13 lymphomatoid papulosis 30.2 ALK GZMB TIA1
14 follicular lymphoma 30.2 BCL6 MME MS4A1
15 hemophagocytic lymphohistiocytosis 30.1 CD5 GZMB IL2RB ITK
16 b-cell lymphomas 30.1 BCL6 CD5 MME MS4A1 SYK TCL1A
17 subcutaneous panniculitis-like t-cell lymphoma 30.1 GZMB NCAM1 TIA1
18 lymphoblastic lymphoma 30.0 BCL6 CD5 MME
19 hepatosplenic t-cell lymphoma 30.0 GZMB TIA1
20 mantle cell lymphoma 29.9 BCL6 CD5 MME SYK
21 pediatric lymphoma 29.9 ALK MME NCAM1 TNFRSF8
22 autoimmune lymphoproliferative syndrome, type v 29.7 ALK BCL6 CD5 TCL1A TIA1
23 sarcoidosis 1 29.7 ALK CXCR3 IL2 IL2RB TNFRSF8
24 lymphoma, mucosa-associated lymphoid type 29.6 BCL6 CD5 CXCL13 CXCR3 MME
25 leukemia, chronic lymphocytic 29.5 BCL6 CD5 CXCR3 IL2 MS4A1 SYK
26 lymphoma, non-hodgkin, familial 28.4 ALK BCL6 CD5 GZMB IL2 IL2RB
27 primary cutaneous peripheral t-cell lymphoma not otherwise specified 12.7
28 enteropathy-associated t-cell lymphoma 11.7
29 primary cutaneous gamma/delta-positive t-cell lymphoma 10.5
30 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.5
31 leukemia 10.4
32 adult t-cell leukemia 10.3
33 t-cell leukemia 10.3
34 hypereosinophilic syndrome 10.3
35 lichen sclerosus et atrophicus 10.3 GZMB TIA1
36 lymphomatoid granulomatosis 10.3 GZMB TIA1
37 viral esophagitis 10.3 GZMB TIA1
38 myelofibrosis 10.3
39 lymphocytic leukemia 10.3
40 lymphocytic gastritis 10.3 GZMB TIA1
41 primary cutaneous anaplastic large cell lymphoma 10.2 ALK GZMB TIA1
42 fixed drug eruption 10.2 CCR4 IL2
43 leukemia, chronic lymphocytic 2 10.2
44 hematopoietic stem cell transplantation 10.2
45 leukemia, b-cell, chronic 10.2
46 erythema multiforme 10.2 CXCR3 GZMB IL2
47 hodgkin's lymphoma, lymphocytic depletion 10.2 ALK TNFRSF8
48 heart lymphoma 10.2 BCL6 MME
49 pityriasis lichenoides 10.2 MS4A1 TNFRSF8
50 sezary's disease 10.2 CCR4 IL2 TNFRSF8

Graphical network of the top 20 diseases related to Peripheral T-Cell Lymphoma:



Diseases related to Peripheral T-Cell Lymphoma

Symptoms & Phenotypes for Peripheral T-Cell Lymphoma

UMLS symptoms related to Peripheral T-Cell Lymphoma:


pruritus

GenomeRNAi Phenotypes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.42 NCAM1 SYK
2 Decreased viability GR00221-A-1 10.42 ALK NME1 SYK
3 Decreased viability GR00221-A-2 10.42 NME1 SYK
4 Decreased viability GR00221-A-3 10.42 SYK
5 Decreased viability GR00221-A-4 10.42 ALK ITK
6 Decreased viability GR00240-S-1 10.42 TIA1
7 Decreased viability GR00301-A 10.42 GZMB ITK
8 Decreased viability GR00342-S-1 10.42 ITK
9 Decreased viability GR00342-S-2 10.42 ITK
10 Decreased viability GR00342-S-3 10.42 ITK
11 Decreased viability GR00381-A-1 10.42 TIA1
12 Decreased viability GR00402-S-2 10.42 ALK BCL6 CCR4 CD5 CXCL13 CXCR3
13 Decreased cell migration GR00055-A-1 9.65 ALK ITK NCAM1 RHOA SYK
14 no effect GR00402-S-1 9.62 ALK BCL6 CCR4 CD5 CXCL13 CXCR3
15 Increased cell migration GR00055-A-3 9.26 ITK NCAM1 RHOA SYK

MGI Mouse Phenotypes related to Peripheral T-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 BCL6 CCR4 CD5 CXCL13 CXCR3 IL2
2 endocrine/exocrine gland MP:0005379 9.91 ALK BCL6 IL2 IL2RB ITK NME1
3 immune system MP:0005387 9.8 BCL6 CCR4 CD5 CXCL13 CXCR3 IL2
4 liver/biliary system MP:0005370 9.17 BCL6 IL2 IL2RB MME NME1 SYK

Drugs & Therapeutics for Peripheral T-Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
2
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009

Drugs for Peripheral T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 1177-87-3
7
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
9
Epirubicin Approved Phase 4,Phase 1,Phase 2,Not Applicable 56420-45-2 41867
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
11
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-24-8 5755
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 1,Phase 2,Not Applicable 2921-57-5
14
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
15
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 302-25-0
16
Methotrexate Approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
17
Vindesine Approved, Investigational Phase 4,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
18
Mechlorethamine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 6006 143
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-30-3 6037
21
Prednisolone hemisuccinate Experimental Phase 4,Phase 1,Phase 2,Not Applicable 2920-86-7
22
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 31703
23
Pirarubicin Investigational Phase 4 72496-41-4
24
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 0
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
28 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
33 Alkylating Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 BB 1101 Phase 4,Phase 2,Phase 1,Early Phase 1
39 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
42 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Methylprednisolone acetate Phase 4,Phase 1,Phase 2,Not Applicable
44 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Prednisolone acetate Phase 4,Phase 1,Phase 2,Not Applicable
49 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
50 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 251)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
3 Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Recruiting NCT03631862 Phase 4 Apatinib;CHOP Regimen
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
5 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Recruiting NCT03150602 Phase 4 Pralatrexate
6 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
7 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
8 Alemtuzumab and CHOP in T-cell Lymphoma Unknown status NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
9 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma Completed NCT00970385 Phase 3 CHOP21;VIP/ABVD
10 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Completed NCT01482962 Phase 3 Alisertib;Pralatrexate;Gemcitabine;Romidepsin
11 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Active, not recruiting NCT01796002 Phase 3 Romidepsin + CHOP;CHOP
12 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL Active, not recruiting NCT03349333 Phase 3 pralatrexate
13 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
14 Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma Not yet recruiting NCT03553537 Phase 3 Decitabine;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone
15 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Not yet recruiting NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
16 Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients Terminated NCT01420679 Phase 3 Pralatrexate Injection
17 A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma Withdrawn NCT01355783 Phase 3 E7777
18 Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
19 Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Unknown status NCT02520219 Phase 2 GDP
20 Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma Unknown status NCT02944812 Phase 2 Chidamide
21 Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma Unknown status NCT00974324 Phase 2 endostar and CHOP
22 Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) Unknown status NCT00632827 Phase 2 REGIMEN;REGIMEN B
23 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Unknown status NCT00211185 Phase 2 ONTAK (denileukin diftitox, DAB389 IL-2)
24 Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) Unknown status NCT00840385 Phase 2 FAD
25 GDP in Frontline Chemotherapy for Patients With PTCL-NOS Unknown status NCT02404571 Phase 2 GDP chemotherapy
26 A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Unknown status NCT00299351 Phase 2 Depsipeptide
27 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28 Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma Unknown status NCT01307592 Phase 2 gemcitabine hydrochloride;lenalidomide;oxaliplatin
29 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
30 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
31 Allo-hNHL (FluBuCy) Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
32 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2 valproic acid
33 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Completed NCT01806337 Phase 2 Alemtuzumab
34 Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma Completed NCT00136565 Phase 2 Velcade;Doxorubicin;Prednisone;Cyclophosphamide;Vindesine;Bleomycin
35 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Completed NCT00865969 Phase 2 PXD101
36 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma Completed NCT00888927 Phase 1, Phase 2
37 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) Completed NCT00930605 Phase 2 CHOP regimen alternate with ESHAP regimen;Alemtuzumab
38 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT00364923 Phase 2 Pralatrexate Injection
39 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma Completed NCT00007345 Phase 2 Romidepsin
40 Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Completed NCT01611142 Phase 2
41 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Completed NCT02013362 Phase 1, Phase 2 Pralatrexate injection
42 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients Completed NCT01822886 Phase 2 Romidepsin, Gemcitabine
43 A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas Completed NCT01280526 Phase 1, Phase 2 Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP;Romidepsin and CHOP
44 Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas Completed NCT00453427 Phase 1, Phase 2 Alemtuzumab (Campath-1H)
45 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
46 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Completed NCT00337987 Phase 2 Ontak;CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
47 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
48 A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT Completed NCT00791947 Phase 2 CHOEP + G-CSF followed by BEAM
49 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Completed NCT02158975 Phase 2 MLN9708
50 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy

Search NIH Clinical Center for Peripheral T-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Peripheral T-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Peripheral T-Cell Lymphoma

Anatomical Context for Peripheral T-Cell Lymphoma

MalaCards organs/tissues related to Peripheral T-Cell Lymphoma:

41
T Cells, B Cells, Thymus, Bone, Nk Cells, Bone Marrow, Liver

Publications for Peripheral T-Cell Lymphoma

Articles related to Peripheral T-Cell Lymphoma:

(show top 50) (show all 915)
# Title Authors Year
1
Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified. ( 30430783 )
2019
2
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. ( 29674443 )
2018
3
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review. ( 29719812 )
2018
4
Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-I^t in peripheral T-cell lymphoma, not otherwise specified. ( 29775622 )
2018
5
Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. ( 29682368 )
2018
6
An autopsy case of peripheral T cell lymphoma occurring in a postpartum woman: a unique case suggesting changes in the immunocharacteristics of lymphoma cells before and after delivery. ( 29788970 )
2018
7
Dual-Positive CD4/CD8 Primary Cutaneous Peripheral T-Cell Lymphoma Previously Classified as Mycosis Fungoides a Tumor D'EmblAce. ( 29794483 )
2018
8
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
9
Central Nervous System Involvement in Peripheral T Cell Lymphoma. ( 29374824 )
2018
10
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma. ( 29974231 )
2018
11
Pathogenesis of Peripheral T Cell Lymphoma. ( 29414251 )
2018
12
STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma. ( 29682185 )
2018
13
Peripheral T-cell lymphoma: novel backbone. ( 29371206 )
2018
14
Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP. ( 29703333 )
2018
15
Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy. ( 29681823 )
2018
16
Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India. ( 29676358 )
2018
17
Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. ( 29269644 )
2018
18
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. ( 29703335 )
2018
19
Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review. ( 29951889 )
2018
20
The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL). ( 29397528 )
2018
21
Decision analysis of up-front autologous hematopoietic stem cell transplantation in patients with peripheral T-cell lymphoma. ( 29795423 )
2018
22
A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. ( 29622656 )
2018
23
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. ( 29672827 )
2018
24
Pseudomonas oryzihabitans bacteremia in a child with peripheral T-cell lymphoma after allogeneic bone marrow transplantation. ( 29878628 )
2018
25
Epstein-Barr virus positive peripheral T cell lymphoma with novel variants in STAT5B of a pediatric patient: a case report. ( 29615001 )
2018
26
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review. ( 29719411 )
2018
27
Peripheral T-cell lymphoma mimicking classic Hodgkin's lymphoma in a patient presenting with fevers of unknown origin. ( 29420242 )
2018
28
Angioimmunoblastic T-cell lymphoma: a rare subtype of peripheral T-cell lymphoma. ( 29636953 )
2018
29
Epstein-Barr virus positive diffuse large B cell lymphoma with G17V RHOA mutation arising from peripheral T cell lymphoma, not otherwise specified. ( 29063178 )
2018
30
Eosinophilic granulomatosis with polyangiitis mimicking peripheral T-cell lymphoma, not otherwise specified. ( 30153088 )
2018
31
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. ( 30522922 )
2018
32
Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. ( 30430419 )
2018
33
Primary sino-orbital peripheral T-cell lymphoma presenting as unilateral periorbital swelling: a case report. ( 30450324 )
2018
34
Rosai Dorfman disease and peripheral T-cell lymphoma: A rare co-occurrence. ( 30464074 )
2018
35
Primary cutaneous peripheral T-cell lymphoma with a late relapse solely in the ileum mimicking monomorphic epitheliotropic intestinal T-cell lymphoma. ( 30477646 )
2018
36
A case of primary cutaneous peripheral T-cell lymphoma, not otherwise specified with cytotoxic phenotype showing multiple ulcers on the entire body. ( 30407644 )
2018
37
Rapidly progressive renal failure due to tubulointerstitial infiltration of peripheral T-cell lymphoma, not otherwise specified accompanied by uveitis: a case report. ( 30409117 )
2018
38
Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. ( 30420593 )
2018
39
Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL). ( 30307363 )
2018
40
Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. ( 30327172 )
2018
41
Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified. ( 30291111 )
2018
42
Comparative Clinicopathological Analysis of Cutaneous Peripheral T-cell lymphoma, Not Otherwise Specified, According to Primary Tumor Site. ( 30296539 )
2018
43
Isolated hypoglossal nerve palsy as a presenting symptom of metastatic peripheral T-cell lymphoma - not otherwise specified (PTCL-NOS): a unique case & a review of the literature. ( 30302235 )
2018
44
Peripheral T-cell lymphoma - are we making progress? ( 30213401 )
2018
45
Corneal Relapse of Peripheral T-Cell Lymphoma Under Systemic Chemotherapy. ( 30222718 )
2018
46
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China. ( 30209556 )
2018
47
Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. ( 29076126 )
2018
48
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. ( 29119842 )
2018
49
Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. ( 29305415 )
2018
50
The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. ( 29479670 )
2018

Variations for Peripheral T-Cell Lymphoma

Copy number variations for Peripheral T-Cell Lymphoma from CNVD:

7 (show all 12)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 88960 14 9867021 9882729 Gain BCL11B Peripheral t-cell lymphoma
2 88988 14 9896938 9916093 Gain CCNK Peripheral t-cell lymphoma
3 88989 14 9896938 9916093 Gain SETD3 Peripheral t-cell lymphoma
4 217122 7 1 59900000 Gain Peripheral t-cell lymphoma
5 226600 7 59900000 159138663 Gain Peripheral t-cell lymphoma
6 250160 9 2032100 2047878 Loss MLLT3 Peripheral t-cell lymphoma
7 250409 9 2120977 2133626 Loss IFNA17 Peripheral t-cell lymphoma
8 250410 9 2120977 2133626 Loss IFNA5 Peripheral t-cell lymphoma
9 250411 9 2120977 2133626 Loss KLHL9 Peripheral t-cell lymphoma
10 250672 9 2189825 2200141 Loss CDKN2A Peripheral t-cell lymphoma
11 250673 9 2189825 2200141 Loss CDKN2B Peripheral t-cell lymphoma
12 250674 9 2189825 2200141 Loss MTAP Peripheral t-cell lymphoma

Expression for Peripheral T-Cell Lymphoma

Search GEO for disease gene expression data for Peripheral T-Cell Lymphoma.

Pathways for Peripheral T-Cell Lymphoma

Pathways related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.17 ALK CCR4 CXCL13 CXCR3 IL2 IL2RB
2
Show member pathways
13.12 CCR4 CXCL13 CXCR3 IL2 IL2RB RHOA
3
Show member pathways
12.71 CCR4 CXCL13 CXCR3 ITK RHOA
4
Show member pathways
12.21 IL2 IL2RB ITK SYK
5
Show member pathways
11.98 CCR4 CXCL13 CXCR3 ITK RHOA SYK
6
Show member pathways
11.96 IL2 IL2RB RHOA SYK
7 11.93 ALK IL2RB ITK SYK
8
Show member pathways
11.86 IL2 IL2RB RHOA SYK
9
Show member pathways
11.82 CCR4 CXCL13 CXCR3
10
Show member pathways
11.81 GZMB IL2 IL2RB
11 11.74 BCL6 GZMB IL2 IL2RB ITK NCAM1
12 11.71 CD5 MME MS4A1
13 11.56 CXCR3 GZMB IL2 IL2RB NCAM1
14 11.54 IL2 MME MS4A1 NCAM1
15 11.5 CD5 IL2 IL2RB MME MS4A1 NCAM1
16
Show member pathways
11.46 GZMB IL2 IL2RB
17 11.28 BCL6 CD5 MME MS4A1 TNFRSF8
18
Show member pathways
11.03 IL2 IL2RB SYK
19 10.74 NME1 RHOA

GO Terms for Peripheral T-Cell Lymphoma

Cellular components related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 ALK CCR4 CD5 CXCR3 IL2RB MME
2 external side of plasma membrane GO:0009897 9.1 CCR4 CD5 CXCR3 IL2RB MS4A1 NCAM1

Biological processes related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.89 ALK BCL6 IL2 IL2RB TCL1A
2 cell chemotaxis GO:0060326 9.65 CCR4 CXCL13 CXCR3
3 chemokine-mediated signaling pathway GO:0070098 9.58 CCR4 CXCL13 CXCR3
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.56 CCR4 CXCL13 CXCR3 IL2
5 positive regulation of regulatory T cell differentiation GO:0045591 9.46 BCL6 IL2
6 positive regulation of alpha-beta T cell differentiation GO:0046638 9.43 RHOA SYK
7 negative regulation of B cell apoptotic process GO:0002903 9.37 BCL6 IL2
8 germinal center formation GO:0002467 9.32 BCL6 CXCL13
9 beta selection GO:0043366 9.16 RHOA SYK
10 leukocyte activation involved in immune response GO:0002366 8.96 IL2 SYK
11 interleukin-2-mediated signaling pathway GO:0038110 8.8 IL2 IL2RB SYK

Molecular functions related to Peripheral T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.8 IL2 IL2RB NCAM1

Sources for Peripheral T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....